Betulinic acid exhibits stronger cytotoxic activity on the normal melanocyte NHEM-neo cell line than on drug-resistant and drug-sensitive MeWo melanoma cell lines

Molecular Medicine Reports

Volumn 2, Issue 4, 2009, Pages 543-548

  Surowiak, Pawel ^a,b,c   Drag, Marcin ^c,d   Materna, Verena ^b   Dietel, Manfred ^b   Lage, Hermann ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

^c WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Betulinic acid; Melanocyte; Melanoma; Multidrug resistance

Indexed keywords

BETULIC ACID; CASPASE 3; CISPLATIN; ETOPOSIDE; FOTEMUSTINE; KI 67 ANTIGEN; SULFORHODAMINE B; VINBLASTINE;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER THERAPY; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; MELANOCYTE; MELANOMA; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 67651087821     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000134     Document Type: Article

References (27)

1. Ho RC: Medical management of stage IV malignant melanoma. Medical issues. Cancer 75: 735-741, 1995.
2. Barth A and Morton DL: The role of adjuvant therapy in melanoma management. Cancer 75: 726-734, 1995.
3. Schadendorf D, Worm M, Algermissen B, Kohlmus CM and Czarnetzki BM: Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity. Cancer 73: 103-108, 1994.
4. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648, 2001.
5. Soengas MS, Capodieci P, Polsky D, et al: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409: 207-211, 2001. (Pubitemid 32144287)
6. Pisha E, Chai H, Lee IS, et al: Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1: 1046-1051, 1995.
7. Zuco V, Supino R, Righetti SC, et al: Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 175: 17-25, 2002. (Pubitemid 33153040)
8. Kim DSHL, Chen ZD, Nguyen VT, et al: A concise semi-synthetic approach to betulinic acid from betulin. Synth Commun 27: 1607-1612, 1997.
9. Gyorffy B, Surowiak P, Kiesslich O, et al: Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118: 1699-1712, 2006. (Pubitemid 43376433)
10. Kowalski P, Surowiak P and Lage H: Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2 and BCRP. Mol Ther 11: 508-522, 2005. (Pubitemid 40353109)
11. Surowiak P, Materna V, Kaplenko I, et al: ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res 12: 7149-7158, 2006. (Pubitemid 44974516)
12. Surowiak P, Materna V, Maciejczyk A, et al: Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch 450: 279-285, 2007. (Pubitemid 46376562)
13. Wick W, Grimmel C, Wagenknecht B, Dichgans J and Weller M: Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J Pharmacol Exp Ther 289: 1306-1312, 1999. (Pubitemid 29246659)
14. Tan Y, Yu R and Pezzuto JM: Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin Cancer Res 9: 2866-2875, 2003. (Pubitemid 36842133)
15. Hata K, Hori K and Takahashi S: Differentiation- and apoptosis-inducing activities by pentacyclic triterpenes on a mouse melanoma cell line. J Nat Prod 65: 645-648, 2002. (Pubitemid 34547402)
16. Schmidt ML, Kuzmanoff KL, Ling-Indeck L and Pezzuto JM: Betulinic acid induces apoptosis in human neuroblastoma cell lines. Eur J Cancer 33: 2007-2010, 1997.
17. Fulda S, Jeremias I, Pietsch T and Debatin KM: Betulinic acid: a new chemotherapeutic agent in the treatment of neuroectodermal tumors. Klin Padiatr 211: 319-322, 1999. (Pubitemid 29364776)
18. Fernandes J, Castilho RO, Da Costa MR, et al: Pentacyclic triterpenes from Chrysobalanaceae species: cytotoxicity on multidrug resistant and sensitive leukemia cell lines. Cancer Lett 190: 165-169, 2003. (Pubitemid 36136015)
19. Jung GR, Kim KJ, Choi CH, et al: Effect of betulinic acid on anticancer drug-resistant colon cancer cells. Basic Clin Pharmacol Toxicol 101: 277-285, 2007. (Pubitemid 350194804)
20. Fulda S and Debatin KM: Sensitization for anticancer drug-induced apoptosis by betulinic acid. Neoplasia 7: 162-170, 2005. (Pubitemid 40315993)
21. Sawada N, Kataoka K, Kondo K, et al: Betulinic acid augments the inhibitory effects of vincristine on growth and lung metastasis of B16F10 melanoma cells in mice. Br J Cancer 90: 1672-1678, 2004. (Pubitemid 38648255)
22. Grottke C, Mantwill K, Dietel M, Schadendorf D and Lage H: Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer 88: 535-546, 2000. (Pubitemid 30805066)
23. Sinha P, Kohl S, Fischer J, et al: Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis 21: 3048-3057, 2000. (Pubitemid 30700736)
24. Lage H, Christmann M, Kern MA, et al: Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int J Cancer 80: 744-750, 1999. (Pubitemid 29066288)
25. Christmann M, Pick M, Lage H, Schadendorf D and Kaina B: Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer 92: 123-129, 2001. (Pubitemid 32187041)
26. Liedert B, Materna V, Schadendorf D, Thomale J and Lage H: Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 121: 172-176, 2003. (Pubitemid 36900469)
27. Lage H, Helmbach H, Grottke C, Dietel M and Schadendorf D: DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Lett 494: 54-59, 2001. (Pubitemid 32289371)